Why CareDx is betting its future on diagnostics and dropping some baggage

CareDx Pivots Strategy to Fuel Profit Growth

A bold divestiture positions the diagnostics leader for precision-driven expansion.

Why Walk Away from $10M in Revenue?

CareDx’s decision to sell its Lab Products division—a maker of global test kits—isn’t a retreat but a calculated move. The unit, once dismissed as complementary to the core business, now clashes with CareDx’s high-growth segments: U.S.-based testing services (+48% revenue growth) and digital tools (+33%). With the company’s financial engine roaring—$118M in total revenue, up 39% year-over-year—hanging onto a side project with barely $10M in sales no longer aligns with strategy.

“Keeping a money-losing side project around doesn’t make sense when other parts of the company are growing fast.”

The Deal: Cash Injection Meets Strategic Control

The transaction delivers three key wins:

$170M Cash Windfall: A substantial capital boost for acquisitions or R&D.
Six-Month Transition Support: Smooth exit from PCR and next-gen sequencing test kits—segments where demand lags.
Exclusive Licensing Rights: Permanent North American rights to post-transplant monitoring tests, securing long-term demand.

“It’s a clean swap—cash for control.”

Stock Market Approval: Shares surged 29% post-announcement, signaling investor confidence in the pivot.

Numbers Don’t Lie

Total Revenue: $118M (+39% YoY)
Testing services: Primary revenue driver
Lab Products: Minimal impact ($10M)
Cash Reserves: $198M (pre-sale) → $368M post-deal, fueling future acquisitions.
Profit Momentum: Rising test volumes + higher price points = stronger margins.

The Bigger Play: Precision Diagnostics

CareDx isn’t just trimming fat—it’s buying into the future. The cash infusion will target complementary businesses, reinforcing its vision of precise, data-driven diagnostics. With a six-month runway to finalize the sale, the company is already eyeing its next strategic move.

What’s Next?

CareDx plans to disclose growth roadmaps in the coming weeks, but one thing is clear: Underperforming assets are out. High-margin, scalable solutions are in.

“The decision to drop underperforming assets while grabbing a strategic licensing deal might just be the smartest move they’ve made.”